摘要
目的:探讨基质金属蛋白酶组织抑制剂TlMP-1、TIMP-2在乳腺癌中的表达及与临床预后的关系。方法:采用组织芯片及免疫组化SP法检测183例乳腺癌组织中TIMP-1、TIMP-2的表达水平。结果:1)乳腺癌组织中TIMP-1和TIMP-2的阳性表达率分别为61.2%和75.4%。乳腺癌组与对照组TIMP-1、TIMP-2的表达具有显著差异(P<0.01)。2)TIMP-1的表达与肿瘤大小有关(P=0.049),与组织学分级有关(P=0.014),与临床TNM分期、淋巴结转移状态密切相关(P均<0.01),而与年龄、月经状态、病理类型以及雌孕激素受体状态无关。TIMP-2的表达与临床TNM分期、淋巴结转移状态密切相关(P均<0.01),而与肿瘤大小、组织学分级、年龄、月经状态、病理类型以及雌孕激素受体状态无关。3)TIMP-1、TIMP-2高表达组10年生存率均高于低表达组(P均<0.01)。结论:TIMP-1、TIMP-2均可作为乳腺癌患者预后判断的指标。
Objective： To detect the expression of TIMP-1 and TIMP-2 in breast cancer and to explore the correlation between this expression and the clinical prognosis. Method： TIMP-1 and TIMP-2 mRNA and protein were detected in 183 patients with breast cancer using microarray and S-P immunohistochemical technique. Results： a） The expression levels of TIMP-1 （61.2%） and TIMP-2 （75.4%） in the breast cancer tissues were significantly higher than those in benign breast diseases （P〈 0.01）. b） TIMP-1 expression was correlated with tumor size （P=0.049） and histological grade （P=0.014）. It was also significantly correlated with the clinical TNM staging and lymph node status, but it had no correlation with age, pathological type, or ER and PR status. TIMP-2 was significantly correlated with clinical TNM staging and lymph node status, but had no correlation with age, tumor size, pathological type, or ER and PR status, c） The 10-year survival rate in the group with overexpression of TIMP-1 and TIMP-2 was higher compared to the group with lower expression of TIMP-1 and TIMP-2. Conclusion： Both TIMP-1 and TIMP-2 can serve as markers for prognosis of breast cancer patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第3期132-135,共4页
Chinese Journal of Clinical Oncology
基金
河北省科技厅科研基金资助(编号:052761689)
关键词
乳腺癌
基质金属蛋白酶
组织金属蛋白酶抑制剂
组织芯片
预后
Breast cancer Matrix metalloproteinase Tissue inhibitors of metalloproteinase （TIMP） Microarray Prognosis
